Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine > News > Real-world evidence in oncology has benefits (and risks)
  • News

Real-world evidence in oncology has benefits (and risks)

  • 13 January 2020
  • Cristina Ferrario
Real-world evidence in oncology has benefits (and risks)
Total
0
Shares
0
0
0
0
0

Despite some weaknesses, real-world data can have a pivotal role in oncology, helping researchers and physicians to better understand the efficacy of anti-cancer treatments and how to manage the side effects.

This is the position expressed in a commentary published in The Oncologists by three Italian experts: Massimo Di Maio from University of Turin, Francesco Perrone from the National Cancer Institute in Naples and Pierfranco Conte from University of Padua.

According to the authors, the analysis of real-world evidence (such as health records and cancer registries) is gaining increasing attention as a useful way to answer questions that randomised controlled trials (RCTs) cannot fully address. “However, caution must be paid to the intrinsic limitations of such data, to avoid a misleading and potentially harmful use” authors warned.

Several applications for real-world evidence have been proposed in recent years like their use to describe the efficacy of a treatment in a “real” population, more similar to the population clinicians see in their daily practice, and not shaped by the very stringent inclusion criteria often established for RCTs. Moreover, real-world evidence can help better understand if a result can be generalized to different sub-populations, or give clues on the optimal treatment sequence, while the majority of RCTs do not address this issue.

And there’s even more than this: real-world evidence is useful to describe the reliability of complex procedures in the clinical practice, to show the effectiveness of interventions in settings where RCT can be extremely challenging, as is the case of rare molecular subgroups, and can be used to establish the safety profile of a drug, especially when it comes to long-term adverse events. “Real-world studies can also give useful information about the compliance or adherence to treatment” Di Maio and colleagues added.

Getting a glimpse of the other side of the coin, it is clear that some characteristics of real-world evidence can limit their use. “The absence of a randomized group does not allow to estimate the efficacy compared with other treatments, and quality of data could be lower compared with clinical trials” said the authors, by way of example.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • cancer registries
  • Francesco Perrone
  • health records
  • Massimo Di Maio
  • oncologist
  • Pierfranco Conte
  • randomised controlled trials
  • rct
  • real-world evidence
  • RWE
Cristina Ferrario

Previous Article
  • Articles
  • Practice Points

Tackling resistance to anti-EGFR therapies, from challenges to re-challenge

  • 7 January 2020
  • Cristina Ferrario
View Post
Next Article
  • News

More data on physical activity and reduction of cancer risk

  • 20 January 2020
  • Alessia De Chiara
View Post
You May Also Like
View Post
  • News

How a Brain-Destroying Protein Became Cancer’s Ally: Alpha-Synuclein Emerges as a New Target in Melanoma

  • Janet Fricker
  • 4 July 2025
View Post
  • News

CancerWorld #105 (July 2025)

  • Yeva Margaryan
  • 2 July 2025
View Post
  • News

How a Chicken Egg Model Could Transform Pediatric Cancer Treatment in Canada

  • Victoria Forster
  • 20 June 2025
View Post
  • News

Microbiota-Derived Bile Acids as Androgen Receptor Antagonists Enhance Anti-Tumour Immunity

  • Janet Fricker
  • 19 June 2025
View Post
  • Articles
  • News

Strategies Needed to Prioritise Screening in Survivors of Childhood Cancer

  • Janet Fricker
  • 4 June 2025
View Post
  • Articles
  • News

CancerWorld #104 (June 2025)

  • Yeva Margaryan
  • 2 June 2025
View Post
  • Articles
  • Medicine
  • News

Common Diabetes Medication Could Protect Heart Health During Cancer Treatment

  • Janet Fricker
  • 30 May 2025
View Post
  • Articles
  • News

CancerWorld issue #103 (May, 2025)

  • Yeva Margaryan
  • 11 May 2025
search
CancerWorld #105 Download CancerWorld #104 Download CancerWorld #103 Download CancerWorld #102 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • How a Brain-Destroying Protein Became Cancer’s Ally: Alpha-Synuclein Emerges as a New Target in Melanoma
    • 4 July 2025
  • CancerWorld #105 (July 2025)
    • 2 July 2025
  • How a Chicken Egg Model Could Transform Pediatric Cancer Treatment in Canada
    • 20 June 2025
  • Microbiota-Derived Bile Acids as Androgen Receptor Antagonists Enhance Anti-Tumour Immunity
    • 19 June 2025
  • Strategies Needed to Prioritise Screening in Survivors of Childhood Cancer
    • 4 June 2025
Article
  • Suheir Rasul: Protecting Human Dignity
    • 4 July 2025
  • Equity:The Word That Shaped Her Career From The Lab To The White House:The Story Of Catharine Young
    • 4 July 2025
  • Curious, Rejected,Accepted: An ESO Fellow’s Road to Becoming an Oncologist
    • 3 July 2025
Social

Would you follow us ?

Contents
  • Suheir Rasul: Protecting Human Dignity
    • 4 July 2025
  • Equity:The Word That Shaped Her Career From The Lab To The White House:The Story Of Catharine Young
    • 4 July 2025
  • Curious, Rejected,Accepted: An ESO Fellow’s Road to Becoming an Oncologist
    • 3 July 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESO College Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.